finasteride and Cancer of Ovary

finasteride has been researched along with Cancer of Ovary in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (66.67)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Gelfond, J; Kabra, A; Liss, MA	1
Henderson, BE; Pike, MC; Ross, RK	1
Nightingale, SL	1

Trials

1 trial(s) available for finasteride and Cancer of Ovary

Article	Year
Hormonal manipulation with finasteride or oral contraception does not influence incidence of renal cell carcinoma. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2018, Volume: 27, Issue:5 Topics: 5-alpha Reductase Inhibitors; Aged; Carcinoma, Renal Cell; Colorectal Neoplasms; Contraception; Contraceptives, Oral; Dutasteride; Female; Finasteride; Follow-Up Studies; Humans; Incidence; Kidney Neoplasms; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Prostatic Hyperplasia; Prostatic Neoplasms; Risk Factors; Self Report	2018

Article

Year

Hormonal manipulation with finasteride or oral contraception does not influence incidence of renal cell carcinoma.

European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2018, Volume: 27, Issue:5

Topics: 5-alpha Reductase Inhibitors; Aged; Carcinoma, Renal Cell; Colorectal Neoplasms; Contraception; Contraceptives, Oral; Dutasteride; Female; Finasteride; Follow-Up Studies; Humans; Incidence; Kidney Neoplasms; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Prostatic Hyperplasia; Prostatic Neoplasms; Risk Factors; Self Report

2018

Other Studies

2 other study(ies) available for finasteride and Cancer of Ovary

Article	Year
Hormonal chemoprevention of cancer in women. Science (New York, N.Y.), 1993, Jan-29, Volume: 259, Issue:5095 Topics: 5-alpha Reductase Inhibitors; Adult; Age Factors; Aged; Androstenes; Anticarcinogenic Agents; Azasteroids; Breast Neoplasms; Contraceptives, Oral; Endometrial Neoplasms; Estrogen Replacement Therapy; Female; Finasteride; Humans; Incidence; Male; Middle Aged; Ovarian Neoplasms; Progestins; Prostatic Neoplasms; Tamoxifen; United Kingdom; United States	1993
From the Food and Drug Administration. JAMA, 1992, Sep-16, Volume: 268, Issue:11 Topics: 5-alpha Reductase Inhibitors; Alkaloids; Androstenes; Antineoplastic Agents, Phytogenic; Azasteroids; Female; Finasteride; Humans; Male; Mammaplasty; Neoplasm Metastasis; Ovarian Neoplasms; Paclitaxel; Prostatic Hyperplasia; Prostheses and Implants; Silicones; United States; United States Food and Drug Administration	1992

Article

Year

Hormonal chemoprevention of cancer in women.

Science (New York, N.Y.), 1993, Jan-29, Volume: 259, Issue:5095

Topics: 5-alpha Reductase Inhibitors; Adult; Age Factors; Aged; Androstenes; Anticarcinogenic Agents; Azasteroids; Breast Neoplasms; Contraceptives, Oral; Endometrial Neoplasms; Estrogen Replacement Therapy; Female; Finasteride; Humans; Incidence; Male; Middle Aged; Ovarian Neoplasms; Progestins; Prostatic Neoplasms; Tamoxifen; United Kingdom; United States

1993

From the Food and Drug Administration.

JAMA, 1992, Sep-16, Volume: 268, Issue:11

Topics: 5-alpha Reductase Inhibitors; Alkaloids; Androstenes; Antineoplastic Agents, Phytogenic; Azasteroids; Female; Finasteride; Humans; Male; Mammaplasty; Neoplasm Metastasis; Ovarian Neoplasms; Paclitaxel; Prostatic Hyperplasia; Prostheses and Implants; Silicones; United States; United States Food and Drug Administration

1992